Health and Fitness Health and Fitness
Thu, February 2, 2012
Wed, February 1, 2012
Tue, January 31, 2012
[ Tue, Jan 31st 2012 ] - Market Wire
00 AM EST
Mon, January 30, 2012
Sat, January 28, 2012
Fri, January 27, 2012
Thu, January 26, 2012
Wed, January 25, 2012
Tue, January 24, 2012
[ Tue, Jan 24th 2012 ] - Market Wire
Quarterly Report I 11/12
[ Tue, Jan 24th 2012 ] - Market Wire
Codexis Announces CFO Departure
Mon, January 23, 2012
Sun, January 22, 2012
Sat, January 21, 2012

iBio, Inc. Listing Deficiency Resolved


//health-fitness.news-articles.net/content/2012/01/27/ibio-inc-listing-deficiency-resolved.html
Published in Health and Fitness on Friday, January 27th 2012 at 4:08 GMT by Market Wire   Print publication without navigation


iBio, Inc. Listing Deficiency Resolved -- NEWARK, Del., Jan. 27, 2012 /PRNewswire/ --

iBio, Inc. Listing Deficiency Resolved

[ ]

NEWARK, Del., Jan. 27, 2012 /PRNewswire/ -- iBio, Inc. (NYSE AMEX: [ IBIO ]) announced today that the NYSE Amex confirmed positive resolution of the Company's previously noted listing deficiency with respect to Section 1003(1)(iv) of the NYSE Amex Company Guide. 

About iBio, Inc.

iBio develops and offers product applications of its iBioLaunch™ platform, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The technology has been applied successfully to proteins difficult or impossible to produce with other methods, as well as proteins representative of most important classes of biologic pharmaceuticals. Advantages of the iBioLaunch platform over other systems include enablement of rapid development and validation of modular, scalable, and optionally robotic, multi-product manufacturing facilities; production time measured in weeks instead of months or more; product entry that is unconstrained by traditional process patents; and significantly lower capital and operating costs for comparable production. Further information is available at: [ www.ibioinc.com ].

Forward-Looking Statements

Statements included in this news release related to iBio, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.

cellpadding="0" cellspacing="0" id="convertedTable" style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; BORDER-COLLAPSE: collapse; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">

Contacts:

 

 

 

Corporate:                                               

  Investor:

Robert Erwin, President                             

  Douglas Beck, CFO

iBio, Inc.                                                    

  iBio, Inc.

302-355-2335                                              

  302-355-0923                      

[ rerwin@ibioinc.com ]                                  

  [ ir@ibioinc.com ]

                                   

 

SOURCE iBio, Inc.

[ Back to top ]

RELATED LINKS
[ http://www.ibioinc.com ]


Publication Contributing Sources